



To view the speaker presentations please click on the speaker name or session title to open the video recording. If no link is available, the speaker has not granted permission for their video to be published.

XVI International Workshop on Chronic Lymphocytic Leukaemia 2015		
Monday 7 September 2015 - Day One: B-Cell Receptor and Signalling		
TIME	SESSION SPEAKER	SESSION TITLE
0730	Registration	
0830	XVI iwCLL 2015 Opening Ceremony	
	Traditional Aboriginal Welcome	
0835	Stephen Mulligan iwCLL 2015 Sydney Workshop Chair and Program Chair CLL Australian Research Consortium Sydney, Australia	Welcome and Introduction
0850	The Hon. Dame Marie Bashir AD, CVO Immediate Past Governor of NSW Immediate Past-Chancellor, University of Sydney Sydney, Australia	Welcome and Introduction
	The B-Cell Receptor Session Chairs: Federico Caligaris Cappio and Nicholas Chiorazzi	
0900	Max D. Cooper Professor of Pathology and Laboratory Medicine Emory University School of Medicine, USA	The B-cell in its 50 th Anniversary Year
0930	Freda Stevenson Professor of Immunology University of Southampton, UK	Human B-cell receptor structure and function in CLL
1000	Chris Goodnow Deputy Director, Garvan Institute of Medical Research Sydney, Australia	B-cell signalling and anergy: corruption of self-tolerance signals by oncogenic mutations
1030	Morning Tea	
	B-cell Receptor – Btk, P13K and Multi-molecular BCR inhibitors - Oral Presentations Session Chairs: Giles Best and Amy Johnson	
1100	Farrukh Awan The Ohio State University Columbus, OH, USA	Phase Ib trial of the PI3K/mTOR inhibitor vixalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or chronic lymphocytic leukemia
1110	Giles Best Royal North Shore Hospital Sydney, Australia	Dual inhibition of PIM and PI3-kinase by IBL-202 is effective against CLL cells cultured under conditions that mimic the hypoxic tumour microenvironment
1120	Susan O'Brien Associate Director for Clinical Science University of California, USA	Duvelisib (IPI-145), an Oral Dual Inhibitor of PI3K- δ,γ , is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
1130	Andrew Zelenetz Memorial Sloan-Kettering Cancer Center New York, NY, USA	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥ 65 years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
1140	Graeme Fraser Juravinski Cancer Centre, McMaster University Ontario, Canada	Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial
1150	Elaine Willmore Newcastle University Newcastle-upon-Tyne, UK	Novel small molecule IKK α inhibitors inhibit non-canonical NF- κ B signaling and survival of primary CLL cells
1200	Lunch	

1300	Janssen Opal Sponsor Symposium Evolving Approaches to Therapy in CLL Are all B-cell receptor inhibitors created equal? Session Chairs: Peter Hillmen and Stephen Mulligan	
	John Gribben Barts Cancer Institute Queen Mary University of London, UK	Update on Ibrutinib
	Steven Coutré Professor of Medicine Stanford University Medical Center, USA	Update on idelalisib + rituximab
	Panel Discussion	ALL
1345	The debate: Will novel targeted agents replace chemotherapy in the management of CLL?	
	Clemens Wendtner Professor of Medicine and Assistant Medical Director University of Cologne, Germany	Chemotherapy will remain the cornerstone of CLL management
	Tait Shanafelt Haematologist and Oncologist Mayo Clinic Hospital, USA	Chemotherapy will not have a role in CLL management in 10 years
	Panel Discussion	ALL
	Flow Cytometry Symposium – Oral Presentations Session Chairs: Andy Rawstron and Florence Cymbalista	
1430	Lei Fan Jiangsu Province Hospital Nanjing, China	CD200 improves the diagnosis and prognostification of chronic lymphocytic leukemia
1440	Andy Rawstron St. James's Institute of Oncology Leeds, UK	Reproducible diagnosis of CLL by flow cytometry: an ERIC & ESCCA harmonisation project
1450	Florence Cymbalista Hôpital Avicenne Bobigny, France	Recent enhancements of Minimal Residual Disease detection by flow cytometry in Chronic Lymphocytic Leukemia: a study of the French CLL-MRD group
1500	Alexander Egle Paracelsus University Salzburg, Austria	MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Maintenance trial
1510	Afternoon Tea	
1540	Celgene Silver Sponsor Symposium Exploring the role of the microenvironment in CLL Therapy	
	Thomas Kipps Professor of Medicine Evelyn and Edwin Tasch Chair in Cancer Research Deputy Director of Research Operations UC San Diego Moores Cancer Center, USA	Identifying key targets in the CLL microenvironment
	William Wierda Professor, Department of Leukemia The University of Texas MD Anderson Cancer Center, USA	Therapeutic Strategies to Target the CLL Microenvironment
	Microenvironment – Oral Presentations Session Chairs: Thomas Kipps and Xavier Badoux	
1610	Loic Ysebaert IUC Toulouse Oncopole Toulouse, France	Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia
1620	Arnon Kater Amsterdam, Netherlands	The CLL/ T-cell/macrophage triad shapes a supportive tumor microenvironment in CLL
1630	Saravanan Pillai ErasmusMC: University Medical Centre Rotterdam Netherlands	Antigenic response and immune modulation determine BCR repertoire and phenotype of chronic lymphocytic leukemia
1640	Januario E. Castro Moores Cancer Center San Diego, CA, USA	PF-06747143: an IgG1 anti-CXCR4 antibody Induces Apoptosis in Chronic Lymphocytic Leukemia
1650	Pablo Opezzo Montevideo, Uruguay	Proteomic Characterization of CLL Exosomes During Disease Evolution
1700	Paolo Ghia Istituto Scientifico San Raffaele, Italy	Crystallographic Evidence Of Autologous Recognition By A Clonotypic B Cell Receptor In Chronic Lymphocytic Leukemia
	iwCLL 2015 Award Presentations Session Chairs: Michael Keating and Michael Hallek	
1710	Kanti Rai Chief of CLL Program, North Shore-Long Island Jewish Medical System, New York, USA	Rai/Binet Medal Presentation
1730	Close	

Tuesday 8 September 2015 - Day Two: Patient Related Risk: Biology and Management	
0730	Registration
0800	Novartis Silver Sponsor Symposium More Evidence, More Options First-Line Treatment of CLL Session Chair: Bryone Kuss
	Peter Hillmen Professor of Experimental Haematology Leeds Institute of Cancer and Pathology, Leeds, UK
	Front-line treatment of CLL: The role of chemo-immunotherapy in the era of novel agents
	Epidemiology Session Chair: Daniel Catovsky
0830	Claire Vajdic Head of the Adult Cancer Program University of New South Wales, Sydney, Australia
	Epidemiology of CLL: Recent data from the InterLymph and Genome Wide Sequencing Studies (GWAS)
	Workshop on CLL in Asia – Oral Presentations Session Chairs: Jian Yong Li and Ligui Qiu
0900	Wei Xu Jiangsu Province Hospital Nanjing, China
	Prognostic Impact of Epstein-Barr Virus-DNA Copy Number at Diagnosis in Chronic Lymphocytic Leukemia
0910	Wei Xu Jiangsu Province Hospital Nanjing, China
	Hepatitis B Virus Reactivation in Patients with Chronic Lymphocytic Leukemia: Results from a Single-center Retrospective Non-interventional Analysis in China
0920	Thomas S.Y Chan & Eric Tse Queen Mary Hospital Hong Kong, China
	Clinicopathological characteristics of CLL in Hong Kong Chinese patients
0930	Colin Phipps & Yuh Shan Lee Singapore
	Epidemiology and clinical demography of CLL in a South Asian patient cohort
0940	Jun Takizawa Niigata University Faculty of Medicine Niigata, Japan
	The characteristic of chronic lymphocytic leukemia in Japan: An interim result of CLLRSG-01 study
0950	Morning Tea
	Elderly Patient and Conventional Therapy – Oral Presentations Session Chairs: Stephen Mulligan and Barbara Eichhorst
1020	Stephen Mulligan iwCLL 2015 Sydney Workshop Chair and Program Chair CLL Australian Research Consortium Sydney, Australia
	Dose-Reduced FCR First-line Therapy in Fit Elderly CLL Patients is Safe, Tolerable, and Highly Effective; First Report of Final Statistical Analysis from End of Study and 12 Month Follow-up of ALLG CLL5 Randomised Dose De-escalation Study
1030	Daniel Catovsky The Institute of Cancer Research London, UK
	Long-term outcomes in the LRF CLL4 trial
1040	Talha Munir St James's Hospital Leeds, UK
	Physical examination of MRD assessment rather than CT-Scans is effective to assess responses in patients treated with Fludarabine-Based Chemoimmunotherapy. Analysis of Patients in the UK NCRI Admire and Arctic Trials
1050	Philip Thompson M.D. Anderson Cancer Center Houston, TX, USA
	Lenalidomide and rituximab in combination as initial treatment of Chronic lymphocytic leukemia: initial results of a phase II study
1100	Francesc Bosch Barcelona, Spain
	GREEN study: preliminary safety results from a phase IIIb trial of obinutuzumab alone or in combination with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukaemia (CLL)
1110	Roche Gold Sponsor Symposium What is the role of patient fitness in the evolving treatment landscape Session Chairs: Constantine Tam and Francesc Bosch
1111	Valentin Goede Hematologist, Oncologist and Gerontologist University of Cologne, Germany
	Understanding the less fit patient –fitness assessment tools and current standard of care based on emerging data
1131	Michael Keating President of CLL Global Foundation, US Professor of Medicine, University of Texas MD Anderson Cancer Center, USA
	How I manage unique toxicities of novel agents in the less fit patient
1146	Michael Hallek Principal Investigator, Deputy Scientific Coordinator University of Cologne, Germany
	The role of novel agents in the less fit patient and how best to combine them in therapies for the future
1201	Q&A
1210	Lunch

Manipulating the Immune System in CLL CLL vs host: impact of CLL cells on host immunity Session Chairs: Nicholas Chiorazzi and Freda Stevenson		
1310	John Gribben Barts Cancer Institute Queen Mary University of London, UK	T cell exhaustion and check-point inhibition
1330	Fabienne Mackay Head of Department of Immunology Monash University, Melbourne, Australia	Cytokine-driven immunosuppression in CLL: implications for therapy
1350	Adrian Wiestner National Heart, Lung, and Blood Institute (NIH) Maryland, USA	B-cells, BCR and hypogammaglobulinaemia
Manipulating the Immune System in CLL – Oral Presentations Session Chairs: Adrian Wiestner and Pablo Oppezco		
1410	Melanie Märklin Tübingen, BW, Germany	Nfat2 regulates anergy induction in ClI through Lck
1420	Alexey Danilov Oregon Health and Science University Portland, OR, USA	Targeting Nedd8 activating enzyme abrogates NF-kappaB and induces DNA damage and checkpoint activation in chronic lymphocytic leukemia B-cells
1430	Jiazhu Wu Nanjing Medical University Nanjing, Jiangsu, China	Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
1440	Natarajan Muthusamy The Ohio State University OH, USA	Beyond Scaffolding- CD37 Tetraspanin as therapeutic target in Leukemia- Mechanism based novel combination opportunities with emerging kinase inhibitors
Economics of the Novel Therapy Era		
1450	Nitin Jain Houston, TX, USA	Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
1500	Afternoon Tea	
1530	Janssen Opal Sponsor Symposium Funding the Equation: Keeping pace with treatment advances and associated cost Moderator: Tony Jones, Presenter, Australian Broadcasting Corporation (ABC TV)	
	Robin Foá European Haematologist, Past-President EHA, Italy	Michael Keating President of CLL Global Foundation, US Professor of Medicine, University of Texas MD Anderson Cancer Center, USA
	Warren Lippiatt CLL Patient, Sydney Member Leukaemia Foundation of Australia Board Sydney, Australia	Andrew Roberts Australian Haematologist Member Australian Pharmaceutical Benefits Advisory Committee Melbourne, Australia
	Brian Koffman CLL Patient and Physician, USA	Adrian Thomas Vice-President Global Market Access, Commercial Strategy Operations and Global Public Health Janssen, Belgium
1700	Review of iwCLL Best Poster Discussants and Session Chairs: Michael Hallek and Devinder Gill	
1715	Poster Viewing Reception Level 4, Hilton Sydney, Drinks and Nibbles	
1830	Close	

Wednesday 9 September 2015 - Day three: Disease Related Risk: Biology and Management	
0730	Registration
	The Genetics of CLL Session Chairs: Davide Rossi and Bryone Kuss
0830	Catherine Wu Medical Oncology, Harvard Medical School Dana-Farber Cancer Institute, USA Driver Mutations in CLL
0900	Carlo Croce Director, Institute of Genetics The Ohio State University, USA MicroRNA
	Genetics – Oral Presentations Session Chairs: Davide Rossi and Bryone Kuss
0920	Lauren Thurgood Adelaide, Australia Segregation of CLL patients based on their cytogenetic background reveals marked differences in global protein expression
0930	Gero Knittel Cologne, Germany Establishment of a pre-clinical in vivo platform spanning low-risk to high-risk CLL
0940	Johnathan Strefford Southampton, UK Telomere length predicts progression and overall survival in chronic lymphocytic leukaemia: data from the UK LRF CLL4 trial
0950	Eva Kimby Stockholm, Sweden Targeted sequencing reveals subclonal complexity of CD49d subpopulations in CLL patients
1000	Morning Tea
1040	Gilead Silver Sponsor Symposium A new era in the treatment of difficult to treat CLL: addressing the unmet need Session Chair: Stephen Mulligan
	Stephen Mulligan iwCLL 2015 Sydney Workshop Chair and Program Chair CLL Australian Research Consortium Sydney, Australia Introduction: Current CLL treatment in specific patient populations – what is the unmet need?
	Jennifer Brown Associate Professor, Harvard Medical School Director, CLL Center, Dana-Farber Cancer Institute, USA Clinical Case Introduction
	Barbara Eichhorst University of Cologne, Germany Evolution of treatment options in CLL
	Jennifer Brown Associate Professor, Harvard Medical School Director, CLL Center, Dana-Farber Cancer Institute, USA From clinical trials to clinical practice: integrating BCR targeted therapies in CLL treatment
	Summary and Close
	“Real-World” Novel and Other Therapies – Oral Presentations Session Chairs: Arnon Kater and Andrew Roberts
1110	Adrian Wiestner National Heart, Lung, and Blood Institute (NIH) Maryland, USA Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
1120	Paula Cramer University of Cologne, Germany Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
1130	Florence Cymbalista Bobigny, France Atrial fibrillation and Ibrutinib : advocacy for guidelines
1140	Constantine Tam Peter MacCallum Cancer Centre Melbourne, Australia Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
1150	Olivier Tournilhac Clermont-Ferrand, France RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based
1200	Lunch

	AbbVie Gold Sponsor Symposium	
1300	Evaluation of P53 Abnormalities in the Evolving Therapeutic Landscape of Chronic Lymphocytic Leukemia	
	Session Chair: John Seymour	
	Susan O'Brien Associate Director for Clinical Science, University of California, USA	Genetic Aberrations in CLL, Including p53 abnormalities, and their impact on patient outcomes
	Davide Rossi Assistant Professor of Hematology, Amedeo Avogadro University of Eastern Piedmont, Italy	Testing for High-Risk CLL: current and future strategies
	John Seymour Chair of the Haematology Service Peter MacCallum Cancer Center, Melbourne	Evolving Treatment Approaches to High-Risk CLL
	Panel discussion, Post Test and Closing Remarks	
	Best of iwCLL Symposium – Oral Presentations	
	Session Chairs: Kanti Rai, Federico Caligaris-Cappio and Stephen Mulligan	
1400	Maria Teresa Sabrina Bertilaccio San Raffaele Scientific Institute Milan, Italy	Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression
1410	Hien Nguyen CECAD Research Center Cologne, Germany	Functional role of LYN kinase in CLL progression - an in vivo analysis
1420	Siddha Kasar Dana-Farber Cancer Institute Boston, MA, USA	Two Distinct Activation-induced Cytidine Deaminase (Aid) Signatures Identified In The Evolution Of Indolent Chronic Lymphocytic Leukemia Using Whole Genome Sequencing
1430	Xiao-Jie Yan Feinstein Institute for Medical Research Manhasset, NY, USA	Over-expression of activation-induced cytidine deaminase in TCL1 mice leads to the development of IGHV-mutated and -unmutated CLL clones that resemble unique subsets of human CLL
1440	Emma Young Uppsala University, Sweden	EGR2 mutations in chronic lymphocytic leukemia- a new bad player?
1450	Anne-Sophie Michallet Lyon, France	Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase IIIb MABLE study
	Closing Ceremony	
1500	Faculty: Kanti Rai, Daniel Catovsky, Federico Caligaris-Cappio, Michael Keating, Michael Hallek, Nicholas Chiorazzi, Carlo Croce, Peter Hillmen and Thomas Kipps Local Organising Committee: Stephen Mulligan, Giles Best, Bryone Kuss, Xavier Badoux and Devinder Gill	
1530	Workshop Close and Afternoon Tea	